Copyright ©The Author(s) 2021.
World J Clin Oncol. Jun 24, 2021; 12(6): 429-436
Published online Jun 24, 2021. doi: 10.5306/wjco.v12.i6.429
Table 1 Review of ten years of research on indoleamine 2,3-dioxygenase in breast cancer patients
2011Yu et al[21]Chinese (n = 26)IDO upregulation inhibits local immune responses by infiltration of T-regs in the tumour microenvironment and promotes metastasis in breast cancer
2011Lyon et al[27]American (n = 33)Increased tryptophan degradation may occur in women with early-stage breast cancer
2012Jacquemier et al[31]French (n = 1749)Immunodetection of IDO-positive cells may be used for diagnosis of medullary breast cancer. IDO has a prognostic significance in basal like breast cancer
2013Soliman et al[24] American (n = 203)IDO expression was higher in ER+ breast cancer than ER breast cancer
2013Yu et al[22]Chinese (n = 85)STAT3-dependent IDO expression induces immunosuppressive effects of MDSCs in breast cancer
2014Bi et al[37]Chinese (n = 110)IDO and EGFR may serve as a potential biomarkers for breast cancer prognosis and treatment
2014Isla Larrain et al[32]Argentinian(n = 91)IDO was expressed in a TNBC subgroup and was involved in the tumour immune escape
2015Salvadori et al[33]Brazilian (n = 20)IDO inhibitor when combined with paclitaxel may be used as a new therapeutic strategy for breast cancer
2017Kim et al[30]South Korean (n = 200)IDO might be an effective immunotherapeutic target in TNBC
2017Dewi et al[25]German (n = 15)IDO-1 expression in ER breast cancer may be associated with poor prognosis. IDO-1 maybe a promising therapeutic target for ER breast cancer
2017Carvajal-Hausdorf et al[36]American (n = 362)IDO-1 quantification has potential to differentiate a population that might get an advantage from IDO-1 blockade
2017Li et al[38]Chinese (n = 46)Expression of IDO and IL-6 is associated with advanced breast cancer and poor response to neoadjuvant chemotherapy
2018Ye et al[34]Chinese (n = 963)IDO and programmed cell death protein-1 pathways might be an effective therapeutic approach in breast cancer treatment
2018Wei et al[23]Chinese (n = 65)IDO may induce angiogenesis in breast cancer, providing a molecular or gene therapy target for angiogenesis inhibition
2018Li et al[39]Chinese (n = 44)Tumour-infiltrating T-regs, MDSCs and IDO expression may be used as a prognostic marker for the outcome of neoadjuvant chemotherapy
2018Dill et al[29]American (n = 281)IDO expression in high-grade,TNBC is associated with PD-L1 co-expression
2019Asghar et al[28]Pakistani (n = 100)IDO expression in TNBC may suggest its role in disease pathogenesis
2019Onseti et al[26]Belgian (n = 202)Kynurenine/tryptophan ratio in plasma might differentiate breast cancer patients from healthy controls
2019Asghar et al[35]Pakistani (n = 100)IDO expression is associated with COX-2 expression in breast cancer patients
2019Zhao et al[40]Chinese (n = 53)IDO expression and activity is linked with advanced breast cancer and poor response to neoadjuvant chemotherapy
2020Wei et al[41]Chinese (n = 77)IDO and tumour infiltrating immune cells can help to evaluate the prognosis of breast cancer patient